Sufenta (Sufentanil)
Highly potent synthetic opioid analgesic for hospital anesthesia and epidural pain management
Sufenta is the original brand of sufentanil, a highly potent synthetic opioid used exclusively in hospitals for anesthesia and perioperative pain management. Approximately 5–10 times more potent than fentanyl and 500–1,000 times stronger than morphine, Sufenta is administered intravenously during major surgery or epidurally for labor analgesia and postoperative pain. Because of its narrow therapeutic window and profound respiratory depressant effects, Sufenta is given only by or under the direct supervision of an anesthesiologist in a facility equipped for mechanical ventilation and resuscitation.
Quick Facts
Key Takeaways
- Sufenta (sufentanil) is one of the most potent opioid analgesics in clinical use and is reserved exclusively for hospital anesthesia, obstetric analgesia, and monitored postoperative pain management.
- It is given intravenously for induction and maintenance of general anesthesia, or epidurally for labor pain, post-cesarean pain, and after major thoracic, abdominal, and orthopedic surgery.
- Respiratory depression is the most serious risk. It may persist into recovery or recur during awakening, so continuous monitoring of breathing, oxygenation, and consciousness is mandatory.
- Concurrent use with benzodiazepines, other CNS depressants, gabapentinoids, or serotonergic agents dramatically increases the risk of life-threatening respiratory depression, serotonin syndrome, and fatal overdose.
- Monoamine oxidase inhibitors (MAOIs) must be discontinued at least 14 days before any procedure involving Sufenta, and partial opioid agonists such as buprenorphine should be stopped to avoid precipitated withdrawal.
What Is Sufenta and What Is It Used For?
Quick Answer: Sufenta is the originator brand name of sufentanil, a potent synthetic opioid of the phenylpiperidine class. It is used in hospitals for induction and maintenance of general anesthesia during major surgery, and epidurally for pain relief after surgery, during labor, and after cesarean delivery. It is not used outside controlled clinical settings.
Sufenta contains the active substance sufentanil, a synthetic opioid analgesic developed in the mid-1970s by Janssen Pharmaceutica as part of the phenylpiperidine family that also includes fentanyl, alfentanil, and remifentanil. Sufenta received its first marketing authorization in the early 1980s and is now available in most countries as a 5 microgram/ml solution for injection, with a higher-strength presentation (Sufenta Forte 50 microgram/ml) marketed in some regions for concentrated anesthetic use. The World Health Organization recognizes sufentanil as a controlled opioid and lists it on its Model List of Essential Medicines for surgical anesthesia.
Pharmacologically, sufentanil is a highly selective agonist at mu-opioid receptors in the central nervous system. Binding at these receptors produces potent analgesia, sedation, and dose-dependent respiratory depression, while cardiovascular effects remain comparatively modest at therapeutic doses — a property that explains why Sufenta is often preferred over less selective opioids for patients with compromised heart function. In terms of relative potency, Sufenta is approximately 5 to 10 times more potent than fentanyl and 500 to 1,000 times more potent than morphine, which means that clinically effective doses are measured in micrograms rather than milligrams.
Sufenta has a rapid onset of action (typically within 1 to 3 minutes after intravenous injection) and a relatively short duration when given as a single bolus, which allows the anesthesiologist to titrate the dose precisely to the surgical stimulus. When given epidurally, sufentanil diffuses into the cerebrospinal fluid and binds to opioid receptors in the spinal cord dorsal horn, producing segmental analgesia without the profound motor block associated with higher concentrations of local anesthetics alone.
The product is supplied as a sterile, clear, colorless solution in glass ampoules. Because of its extreme potency and potential for misuse, Sufenta is classified as a controlled substance in virtually every country, with strict regulations governing its storage, prescription, and administration.
Intravenous Uses in Adults
Intravenous Sufenta is used as the analgesic component of balanced general anesthesia for procedures ranging from short elective operations to complex cardiac, thoracic, neurological, and major abdominal surgery. In a typical balanced technique, Sufenta is combined with a hypnotic agent such as propofol or thiopental, a muscle relaxant, and a volatile anesthetic or further opioid infusion. The rapid onset allows effective obtundation of the stress response at intubation and during major surgical stimulation, while the short duration of a bolus dose gives the anesthesiologist flexibility to manage changing surgical requirements.
In cardiovascular and thoracic surgery, higher doses of Sufenta may be used as a primary anesthetic technique. This “high-dose opioid anesthesia” provides exceptional hemodynamic stability and is particularly valuable in patients with severely impaired cardiac function or those undergoing cardiopulmonary bypass. Mechanical ventilation is mandatory throughout and for some time afterward, because the respiratory depressant effect at these doses substantially outlasts the analgesic action.
Epidural Uses in Adults
Epidural Sufenta is delivered into the epidural space through a catheter, either as a single bolus or as a continuous infusion. This route is used for postoperative analgesia after major abdominal, thoracic, and orthopedic surgery; for labor analgesia; and for pain relief after cesarean delivery. Compared with intravenous administration, epidural sufentanil provides more selective analgesia with lower systemic opioid exposure, less sedation, and a reduced need for systemic rescue analgesia. It is frequently combined with a dilute local anesthetic such as bupivacaine or ropivacaine to achieve synergistic analgesia at lower doses of each agent.
In obstetric practice, epidural Sufenta is widely used during labor and delivery because it allows the mother to remain conscious, cooperative, and able to push effectively while still achieving substantial pain relief. Because systemic absorption from the epidural space is limited, fetal opioid exposure is considerably lower than with equivalent intravenous doses, although neonatal respiratory function is still assessed by the obstetric and neonatal teams.
Use in Children
Intravenous sufentanil may be used in children older than one month for analgesia during induction and maintenance of combined anesthesia. The dose is individualized by the anesthesiologist based on body weight, the nature and duration of the procedure, and the concurrent use of hypnotics, inhalational agents, and muscle relaxants. Intravenous use is not recommended during the neonatal period (under one month of age) due to limited safety data and the heightened sensitivity of neonates to opioid-induced respiratory depression.
Epidural sufentanil is approved in children aged one year and older for the management of postoperative pain after general, thoracic, or orthopedic surgery. Pediatric epidural administration is performed only by anesthesiologists with specific training in pediatric regional anesthesia, and children are monitored for respiratory depression for at least two hours after each epidural dose.
Sufenta is never dispensed to patients for home use or self-administration. It is administered only by specialist physicians — principally anesthesiologists — in operating rooms, intensive care units, or specialized pain management facilities equipped with artificial ventilation, pulse oximetry, capnography, and immediate access to the opioid reversal agent naloxone.
What Should You Know Before Taking Sufenta?
Quick Answer: Sufenta must not be used in patients with respiratory disease causing breathing difficulties, in those taking monoamine oxidase inhibitors (MAOIs), or in patients with acute intermittent porphyria. Caution is required in patients with lung, liver, kidney, or thyroid disease, low blood volume, raised intracranial pressure, obesity, or a history of substance use disorder.
Before Sufenta is administered, the anesthesiologist performs a thorough preoperative assessment that covers medical history, current medications, known allergies, prior experiences with anesthesia, substance use, and relevant laboratory and imaging results. Because Sufenta has such a narrow margin between therapeutic and harmful doses, identifying contraindications and high-risk features is essential to safe use. Patients are encouraged to disclose all prescription medicines, over-the-counter drugs, herbal remedies, recreational drugs, and alcohol use, as any of these can influence opioid pharmacology.
Contraindications — Intravenous Use
Intravenous Sufenta must not be used in the following situations:
- Hypersensitivity to sufentanil, any other opioid analgesic, or any of the excipients (sodium chloride, citric acid monohydrate, water for injections).
- Respiratory disease with significant breathing difficulty, including severe asthma, severe chronic obstructive pulmonary disease (COPD), acute respiratory failure, or untreated obstructive sleep apnea.
- Current or recent use of MAO inhibitors such as phenelzine, tranylcypromine, isocarboxazid, or moclobemide. These must be stopped at least 14 days before any procedure involving Sufenta.
- Acute intermittent porphyria, a rare inherited disorder of heme biosynthesis, in which opioids may trigger life-threatening attacks.
- Current or recent use of partial opioid agonists/antagonists such as buprenorphine, nalbuphine, or pentazocine. These may precipitate withdrawal and reduce Sufenta's analgesic efficacy.
- During labor or before the umbilical cord is clamped at cesarean section by the intravenous route, due to placental transfer and the risk of neonatal respiratory depression.
Contraindications — Epidural Use
In addition to the above, epidural Sufenta is contraindicated in:
- Severe hemorrhage or hypovolemic shock
- Severe systemic infection or septicemia
- Infection at or near the proposed injection site
- Impaired wound healing at the injection site
- Significant coagulopathy or ongoing anticoagulant therapy that would raise the risk of epidural hematoma
- Patient refusal or inability to cooperate with the procedure
Warnings and Precautions
Even when not strictly contraindicated, several conditions require additional caution, dose adjustment, or extended monitoring when Sufenta is used. Inform your anesthesiologist if you have any of the following:
- Abnormally slow intestinal motility or persistent constipation
- Disease of the gallbladder, pancreas, or biliary tract
- Personal or family history of alcohol use disorder or substance use disorder
- Current or previous tobacco or nicotine use
- Mental health conditions including depression, anxiety, post-traumatic stress disorder, or personality disorders
- Lung disease with reduced pulmonary reserve, including asthma, COPD, or interstitial lung disease
- Liver or kidney impairment, which may reduce drug clearance and prolong effects
- Thyroid disorders, particularly untreated hypothyroidism
- Adrenal insufficiency
- Obesity (extended postoperative monitoring is recommended because lipid-soluble opioids may accumulate and produce delayed respiratory depression)
- Raised intracranial pressure, recent head injury, or brain tumor
- Reduced circulating blood volume (hypovolemia) or uncorrected dehydration
- Obstructive sleep apnea or central sleep apnea
- Prolonged QT interval or other serious cardiac arrhythmias
Like all potent opioids, Sufenta causes dose-dependent respiratory depression that is the leading cause of serious adverse outcomes with this drug. Depression of respiration may persist into the postoperative recovery period or recur unexpectedly as residual drug redistributes from peripheral tissues. Sufenta can also provoke or worsen sleep-related breathing disorders, including sleep apnea and sleep-related hypoxemia. Continuous monitoring of respiratory rate, oxygen saturation, and end-tidal carbon dioxide is the standard of care during and after administration. Patients should report any nighttime awakenings with breathlessness, witnessed apneas, or unexplained daytime drowsiness.
Repeated exposure to opioid analgesics, including sufentanil, can lead to reduced effectiveness (tolerance), physical dependence, and, in predisposed individuals, opioid use disorder. While the risk of developing a substance use disorder from hospital-based surgical use is substantially lower than from prolonged outpatient opioid prescribing, it is not zero. Patients with a personal or family history of addiction, mental health conditions, or adolescent substance use should be identified preoperatively so that monitoring and post-discharge pain management can be adapted accordingly.
Pregnancy and Breastfeeding
Pregnancy: Sufenta must not be given intravenously during labor or before the umbilical cord has been clamped at cesarean section, because sufentanil crosses the placenta rapidly and can depress the newborn's breathing. Outside of this specific situation, Sufenta may be used during pregnancy when the anesthesiologist judges that the benefits outweigh the risks — for example, for non-obstetric surgery. Epidural Sufenta is widely accepted for labor analgesia because systemic absorption from the epidural space is low and transfer to the fetus is minimal.
Breastfeeding: Sufentanil is excreted in breast milk in small amounts. Current expert guidance, including that of the European Society of Anaesthesiology and Intensive Care, suggests that breastfeeding may be safely resumed approximately 24 hours after the last dose of sufentanil. During this interval, expressing and discarding milk (“pump and dump”) helps maintain supply. If high doses have been used, or if the newborn is premature or otherwise vulnerable, the waiting period may be extended on an individual basis.
Neonates and Infants
Newborns and young infants are particularly sensitive to opioid-induced respiratory depression. Only limited pharmacokinetic data exist for intravenous sufentanil in this age group, and accurate dose individualization is difficult. For this reason, intravenous Sufenta is not recommended during the neonatal period, and epidural Sufenta is not recommended in children under one year of age. When Sufenta must be used in these groups — for example, for complex cardiac surgery — it is administered by pediatric anesthesiologists under continuous cardiorespiratory monitoring with immediate access to airway equipment and naloxone.
Driving and Operating Machinery
After receiving Sufenta, patients must not drive, cycle, operate machinery, or make important legal or financial decisions for at least 24 hours, and preferably longer if sedation persists. The sedative and psychomotor effects of sufentanil — even after a single intraoperative dose — can impair reaction time, judgment, and coordination. Patients leaving the hospital after an outpatient procedure should be escorted home by a responsible adult.
How Does Sufenta Interact with Other Drugs?
Quick Answer: Sufenta has clinically important interactions with MAO inhibitors (contraindicated), benzodiazepines and other CNS depressants (severe respiratory depression), gabapentin and pregabalin (increased overdose risk), SSRIs and SNRIs (serotonin syndrome), partial opioid agonists (precipitated withdrawal), and CYP3A4 inhibitors such as ketoconazole, erythromycin, and ritonavir (prolonged and enhanced opioid effects).
Because Sufenta is pharmacologically very potent, drug interactions can be rapidly life-threatening if not anticipated. Your anesthesia team must be told about every medication you take — prescription, over-the-counter, herbal, and recreational — including drugs taken weeks before the procedure. The most clinically important interactions are summarized below.
Major Interactions — Contraindicated or Avoid
| Drug / Drug Class | Interaction Effect | Clinical Recommendation |
|---|---|---|
| MAO Inhibitors (phenelzine, tranylcypromine, isocarboxazid, moclobemide) | Serotonin syndrome, severe hypertension or hypotension, hyperpyrexia, and potentially fatal cardiovascular collapse | Contraindicated. Must be discontinued at least 14 days before surgery. |
| Benzodiazepines (midazolam, diazepam, lorazepam, alprazolam) | Profound sedation, severe respiratory depression, coma, and death | Avoid combination when possible; if essential, use lowest effective doses with continuous monitoring. |
| Partial opioid agonists/antagonists (buprenorphine, nalbuphine, pentazocine, butorphanol) | May precipitate acute opioid withdrawal and reduce Sufenta's analgesic efficacy | Contraindicated. Discontinue before Sufenta use and transition under expert supervision. |
| SSRIs and SNRIs (fluoxetine, paroxetine, sertraline, venlafaxine, duloxetine) | Increased risk of serotonin syndrome — agitation, tremor, hyperreflexia, hyperthermia, autonomic instability | Not recommended routinely. Weigh benefit against risk and monitor for serotonergic toxicity. |
| Gabapentin / Pregabalin | Increased risk of opioid overdose, profound sedation, respiratory depression, and death | Use with caution; avoid unnecessary coprescription and monitor respiratory function closely. |
| Alcohol and illicit CNS depressants | Synergistic respiratory depression, unpredictable sedation, and increased mortality risk | Disclose all substance use preoperatively; avoid alcohol for at least 24 hours after Sufenta. |
Moderate Interactions — Use with Caution
| Drug / Drug Class | Interaction Effect | Clinical Recommendation |
|---|---|---|
| Barbiturates, sedatives, hypnotics (thiopental, phenobarbital, zolpidem) | Enhanced CNS and respiratory depression | Reduce doses of both agents; monitor respiration and level of consciousness. |
| Neuromuscular blocking agents (rocuronium, vecuronium, succinylcholine) | Sufentanil may enhance and prolong neuromuscular blockade; increases risk of bradycardia with succinylcholine | Adjust dosing; monitor neuromuscular function with a peripheral nerve stimulator. |
| Inhaled anesthetics (sevoflurane, desflurane, isoflurane, nitrous oxide) | Synergistic CNS and cardiovascular depression; reduced MAC of the inhalational agent | Titrate inhalational agent downward when Sufenta is used; standard balanced anesthesia protocols. |
| Neuroleptics / Antipsychotics (haloperidol, quetiapine, olanzapine) | Additive sedation, risk of hypotension, and QT prolongation | Monitor blood pressure, ECG, and level of consciousness. |
| Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, erythromycin, ritonavir, grapefruit juice) | Increased plasma sufentanil concentration; prolonged and enhanced opioid effects | Reduce Sufenta dose; extend respiratory monitoring; avoid grapefruit juice for 72 hours. |
| Strong CYP3A4 inducers (rifampicin, phenytoin, carbamazepine, St John's wort) | Reduced plasma sufentanil concentration and potentially inadequate analgesia | Titrate to effect; anticipate higher dose requirements. |
| Antihypertensives and diuretics | Additive hypotension, particularly in volume-depleted patients | Optimize volume status preoperatively; monitor blood pressure continuously. |
Sufentanil is primarily metabolized in the liver and small intestine by the cytochrome P450 3A4 (CYP3A4) enzyme system. Co-administration of strong CYP3A4 inhibitors — for example, azole antifungals (ketoconazole, itraconazole), macrolide antibiotics (erythromycin, clarithromycin), HIV protease inhibitors (ritonavir, atazanavir), and even dietary grapefruit juice — can substantially increase sufentanil plasma levels and prolong its effects. Conversely, CYP3A4 inducers (rifampicin, phenytoin, carbamazepine, St John's wort) can reduce efficacy. Your anesthesiologist will take these interactions into account when planning your anesthetic.
What Is the Correct Dosage of Sufenta?
Quick Answer: The dose of Sufenta is individualized by the anesthesiologist according to age, body weight, medical history, type and duration of surgery, and concurrent anesthetic agents. Typical adult intravenous induction doses range from 0.25 to 8 mcg/kg depending on whether Sufenta is a supplement or the primary anesthetic. Epidural doses are considerably lower and are often combined with a local anesthetic.
Sufenta is never self-administered. All doses are prescribed and given by an anesthesiologist or other physician experienced in potent opioid pharmacology, in facilities equipped for continuous cardiorespiratory monitoring, artificial ventilation, and advanced life support. Because effective and toxic doses are separated by a narrow margin, precise titration is essential. The following ranges are illustrative and reflect standard international practice; the actual dose will be chosen by the attending physician based on the clinical situation.
Adults — Intravenous Use
Analgesic Supplement to General Anesthesia
When Sufenta is used as the analgesic component of a balanced anesthetic technique, typical initial intravenous bolus doses range from 0.5 to 5 micrograms per kilogram of body weight. Supplemental doses of 10 to 50 micrograms (approximately 0.15 to 0.7 mcg/kg) are given in response to surgical stimulation or haemodynamic changes. The timing and quantity of supplemental doses are guided by the patient's response, the stage of surgery, and the concurrent use of hypnotic and inhalational agents.
Primary Anesthetic Agent for Major Surgery
For high-dose opioid anesthesia in major cardiac, thoracic, or vascular surgery, Sufenta is administered as a loading dose of 8 to 30 micrograms per kilogram (and occasionally higher), followed by intermittent boluses or a continuous infusion. This technique provides pronounced cardiovascular stability and is particularly valuable for patients with compromised myocardial function, but it requires postoperative mechanical ventilation because respiratory depression substantially outlasts the analgesic effect.
Adults — Epidural Use
Postoperative Pain Management
For epidural analgesia after surgery, typical initial bolus doses are 30 to 50 micrograms of sufentanil diluted in 10 ml of saline. Maintenance is provided either by intermittent boluses (25 micrograms) approximately every hour as needed, or as a continuous epidural infusion. Sufentanil is frequently co-administered with a dilute local anesthetic such as bupivacaine 0.125 percent or ropivacaine 0.2 percent, which improves analgesic quality at lower doses of each agent.
Labor Analgesia
During labor, epidural sufentanil is typically given as an initial bolus of 10 to 15 micrograms combined with 10 ml of dilute bupivacaine or ropivacaine. Maintenance is most commonly achieved by continuous infusion or patient-controlled epidural analgesia (PCEA) at low doses, titrated to the mother's comfort. This regimen provides reliable pain relief while allowing the laboring woman to remain alert and to push effectively in the second stage of labor.
Post-Cesarean Pain Relief
After cesarean delivery, epidural Sufenta (typically 10 to 25 micrograms, often in combination with a local anesthetic) provides several hours of segmental analgesia and facilitates early mobilization, breastfeeding, and bonding with the newborn. All neonates exposed indirectly to sufentanil via this route are observed for signs of respiratory depression, although clinically significant effects are uncommon at recommended epidural doses.
Children
Intravenous Use (Children Older Than 1 Month)
Intravenous Sufenta in children is dosed by body weight and type of surgery. Typical induction doses range from 0.2 to 1 microgram per kilogram, with supplementation as needed throughout the procedure. In neonates older than one month undergoing cardiac surgery, higher doses (5 to 15 mcg/kg) may be used under specialist supervision with planned postoperative ventilation. Continuous monitoring of oxygenation, ventilation, heart rate, and blood pressure is mandatory.
Epidural Use (Children 1 Year and Older)
Epidural Sufenta is administered slowly by an anesthesiologist experienced in pediatric regional anesthesia, with the dose based on weight, level of block, and concurrent anesthetic agents. Children must be monitored for respiratory depression for at least two hours after administration and, in the case of continuous infusion, throughout the entire period of opioid exposure and for several hours afterward.
Special Populations Requiring Dose Adjustment
- Elderly patients: Older adults are more sensitive to Sufenta because of reduced clearance, changes in body composition (greater fat compartment), and age-related changes in the central nervous system. Initial doses are reduced, often by 30 to 50 percent, and titration proceeds cautiously.
- Hepatic impairment: Sufentanil is primarily metabolized in the liver. In moderate to severe liver disease, clearance may be markedly reduced and initial doses should be lowered with extended postoperative monitoring.
- Renal impairment: Renal elimination plays a minor role in sufentanil clearance, but accumulation of the parent drug and inactive metabolites may occur in severe renal failure. Dose adjustment and extended monitoring are prudent.
- Hypothyroidism: Patients with untreated hypothyroidism show enhanced and prolonged opioid effects. Use reduced doses and monitor carefully.
- Obesity: Dosing should generally be based on lean body weight or adjusted body weight to avoid relative overdose, and postoperative respiratory monitoring is extended because lipid-soluble opioids redistribute from fat stores.
- Debilitated patients: Patients who are malnourished, frail, or in poor general condition require reduced doses and vigilant monitoring.
- Opioid-tolerant patients: Those on chronic opioid therapy may require higher intraoperative doses to overcome tolerance. Perioperative planning should involve a pain or addiction medicine specialist when possible.
Missed Dose
Because Sufenta is given only during controlled clinical procedures and never taken at home, the concept of a “missed dose” does not apply in the conventional sense. If a planned intraoperative top-up or epidural bolus is not given in time, the anesthesiologist will re-titrate analgesia using clinical signs, patient-reported pain scores, and vital parameters. Patients do not need to take any action in relation to missed doses.
Overdose
Because Sufenta is administered under carefully controlled conditions, accidental overdose in a hospital setting is rare. Should it occur, features include severe respiratory depression or apnea, pinpoint pupils (miosis), profound sedation or coma, marked bradycardia, hypotension, chest wall rigidity, and, in extreme cases, cardiovascular collapse. Management requires immediate airway and ventilatory support, cardiovascular resuscitation as needed, and administration of the opioid antagonist naloxone, which is kept immediately available wherever Sufenta is used. Repeated doses or a continuous naloxone infusion may be necessary because the half-life of sufentanil can exceed that of naloxone.
If a patient recovering from Sufenta develops slow or stopped breathing, unresponsiveness, or blue discoloration of the lips, call for immediate medical help and begin basic life support. Hospital staff will administer naloxone and support ventilation. Outside a healthcare facility, call your local emergency number at once — do not delay professional care.
What Are the Side Effects of Sufenta?
Quick Answer: The most common side effects of Sufenta are sedation and itching (pruritus), affecting more than 1 in 10 patients. Common effects include nausea, vomiting, blood pressure changes, rapid heart rate, fever, dizziness, headache, and urinary retention. Serious but uncommon complications include respiratory depression or arrest, severe bradycardia, chest wall rigidity, severe allergic reactions, and cardiac arrest.
Like all opioid analgesics, Sufenta can cause side effects. The pattern and severity depend on the dose, the route of administration (intravenous or epidural), the duration of use, and individual patient factors such as age, comorbidities, and concurrent medications. In hospital, side effects are identified and managed promptly by the anesthesia and nursing team; patients should still report any unusual or distressing symptoms.
The frequencies below follow the international pharmacovigilance convention used in the European Summary of Product Characteristics and the British National Formulary.
Very Common
May affect more than 1 in 10 patients
- Sedation (drowsiness, sleepiness, prolonged recovery)
- Pruritus (itching), particularly after epidural administration
Common
May affect up to 1 in 10 patients
- Nausea and vomiting
- Hypertension (high blood pressure) or hypotension (low blood pressure)
- Tachycardia (rapid heart rate)
- Pallor (paleness)
- Cyanosis in neonates (bluish tint of skin or lips)
- Skin discoloration, flushing
- Muscle twitching or involuntary movements
- Urinary retention or urinary incontinence
- Fever and chills
- Headache and dizziness
- Involuntary muscle movements in neonates
- Dry mouth and constipation
Uncommon
May affect up to 1 in 100 patients
- Cardiac arrhythmia (irregular heartbeat)
- Decreased muscle tone in neonates
- Back pain or pain at the epidural site
- Hypersensitivity reactions (rash, urticaria)
- Rhinitis (runny nose)
- Apathy or nervousness
- Impaired muscle coordination (ataxia)
- Sustained involuntary muscle contractions (dystonia)
- Hyperreflexia (exaggerated reflexes)
- Increased muscle tone (hypertonia)
- Reduced intestinal motility in neonates
- Visual disturbances, blurred vision
- Allergic skin reaction, abnormal sweating, dry skin
- Intraoperative myoclonus (sudden muscle jerks)
- Chills or body temperature fluctuations
- Respiratory difficulty or bronchospasm
- Bradycardia (slow heart rate)
- Cough, hiccups, or voice changes
- Cyanosis in adults
- ECG abnormalities
- Chest wall rigidity that can impair ventilation
- Injection site reaction or localized pain
- Skin rash in neonates
Rare / Not Known Frequency
Cannot be estimated reliably from available data
- Miosis (pinpoint pupils)
- Severe respiratory depression or respiratory arrest
- Anaphylaxis (life-threatening allergic reaction with rash, airway swelling, hypotension)
- Euphoria or dysphoria
- Involuntary movements (dyskinesia)
- Cardiac arrest
- Laryngospasm or bronchospasm
- Vertigo or a spinning sensation
- Coma
- Seizures (convulsions)
- Pulmonary edema (fluid in the lungs)
- Severe muscle rigidity or spasm
- Opioid-induced hyperalgesia with prolonged use
- Adrenal insufficiency with very prolonged use
- Serotonin syndrome (in combination with serotonergic drugs)
Side Effects in Children
The qualitative pattern of side effects in children and adolescents is similar to that observed in adults. However, neonates and infants are more prone to respiratory depression and may show additional effects including cyanosis, involuntary muscle movements, and decreased muscle tone. Because weight-based dosing errors can have serious consequences in small patients, pediatric Sufenta administration is performed only by experienced pediatric anesthesiologists with continuous monitoring.
Long-Term and Withdrawal Effects
Short-term perioperative use of Sufenta rarely causes clinically significant dependence. After prolonged use (for example, in intensive care sedation lasting many days), physical dependence can develop and abrupt cessation may trigger an opioid withdrawal syndrome. Symptoms include restlessness, sweating, tearing of the eyes, runny nose, yawning, abdominal cramps, muscle aches, and insomnia. Gradual dose reduction under medical supervision minimizes withdrawal symptoms.
If you experience side effects after receiving Sufenta — including any not listed above — inform your healthcare provider. You can also report side effects directly to your national medicines regulatory authority (for example, the MHRA Yellow Card scheme in the United Kingdom, the FDA MedWatch program in the United States, or your national pharmacovigilance center in the European Union). Reporting side effects contributes valuable real-world safety information and helps improve care for future patients.
How Should You Store Sufenta?
Quick Answer: Sufenta ampoules are stored below 25°C, protected from light in their original carton, and kept secure in accordance with national controlled substances regulations. Once opened, the solution is for immediate single use, and any unused medicine is discarded. Patients do not store Sufenta at home.
Sufenta is an internationally controlled narcotic substance, and hospitals are legally required to store and handle it under strict security arrangements. These arrangements typically include a double-locked cupboard, a controlled drugs register, and reconciliation of all doses administered and discarded. Patients are not normally responsible for Sufenta storage, but understanding these requirements helps explain the procedures observed in hospital.
- Temperature: Store below 25°C (77°F). Do not freeze. Protect the ampoules from temperature extremes during transport.
- Light protection: Keep ampoules in the outer carton to protect from light. Sufentanil is chemically stable but prolonged light exposure should be avoided.
- Use after opening: Sufenta is supplied as a single-use preparation. Once an ampoule is opened, the solution should be used immediately and any unused portion discarded according to controlled-substance procedures.
- Diluted solution stability: For infusions, chemical and physical in-use stability of diluted solutions has been demonstrated for up to 24 hours at 25°C. From a microbiological standpoint, dilutions should be used immediately; if not used immediately, storage conditions are the responsibility of the user and should not normally exceed 24 hours at 2 to 8°C unless dilution has been performed under controlled and validated aseptic conditions.
- Expiry date: Do not use after the expiry date stated on the label and carton. The expiry date refers to the last day of the stated month.
- Visual inspection: Before use, inspect the solution. Do not use if it is discolored, cloudy, contains particles, or if the ampoule is cracked or otherwise damaged.
- Security and disposal: Unused or expired Sufenta must be destroyed under witnessed conditions in line with local controlled-substance regulations. It must never be flushed or placed in household waste.
- Child and pet safety: Because of extreme potency, even trace exposure could be dangerous. Sufenta must never be accessible to children, visitors, or unauthorized staff.
Hospital pharmacists and anesthesia departments are collectively responsible for correct storage, documentation, dispensing, and destruction of Sufenta. These safeguards are both clinical and legal, because misappropriation of potent opioids is a recognized problem in healthcare settings worldwide.
What Does Sufenta Contain?
Quick Answer: The active substance is sufentanil (as sufentanil citrate). Excipients are sodium chloride, citric acid monohydrate, and water for injections. Sufenta is a clear, colorless solution supplied in glass ampoules at a strength of 5 micrograms/ml.
Active Substance
The active pharmaceutical ingredient is sufentanil, present in the formulation as sufentanil citrate. Each milliliter of solution contains 5 micrograms of sufentanil (equivalent to approximately 7.5 micrograms of sufentanil citrate).
| Ampoule Volume | Sufentanil Content | Sufentanil Citrate Content | Typical Use |
|---|---|---|---|
| 2 ml | 10 mcg | 15 mcg | Small bolus doses; pediatric use |
| 5 ml | 25 mcg | 37.5 mcg | Standard intraoperative bolus |
| 10 ml | 50 mcg | 75 mcg | Larger bolus or continuous infusion |
| 20 ml | 100 mcg | 150 mcg | Infusion reservoir in major surgery |
Inactive Ingredients (Excipients)
- Sodium chloride: Adjusts the osmolality of the solution to make it isotonic with body fluids and compatible with intravenous and epidural administration.
- Citric acid monohydrate: Acts as a pH adjuster and buffer to maintain solution stability. Sufenta is formulated at a slightly acidic pH to ensure that sufentanil remains in solution and chemically stable over its shelf life.
- Water for injections: Highly purified pharmaceutical-grade water that serves as the solvent base.
Sodium content: Sufenta contains a small amount of sodium — less than 1 mmol (23 mg) per ampoule — which is considered essentially “sodium-free” by international regulatory definitions and is not clinically relevant for patients on sodium-controlled diets.
Physical Appearance and Packaging
Sufenta is a clear, colorless, sterile solution supplied in colorless glass ampoules. Pack sizes vary by country and market, but typically include cartons of 5 or 10 ampoules per strength and volume. Not all pack sizes may be marketed in every country, and availability depends on national registration and distribution agreements.
Compatibility Information for Healthcare Professionals
Sufentanil citrate solution is chemically compatible with the most commonly used parenteral vehicles, including Ringer's lactate solution, 0.9% sodium chloride solution, and 5% glucose solution. For epidural analgesia it is frequently mixed with 0.9% sodium chloride and/or local anesthetics such as bupivacaine 0.125 percent and ropivacaine 0.2 percent to produce combined opioid/local-anesthetic mixtures. Sufentanil citrate is physically incompatible with several agents that should not be mixed in the same syringe or infusion line — notably diazepam, lorazepam, phenobarbital sodium, phenytoin sodium, and thiopental sodium. Drug compatibility should always be confirmed against local pharmacy guidance before admixture.
Frequently Asked Questions About Sufenta
Sufenta (sufentanil) is a potent opioid analgesic used only in hospital settings. Intravenously, it provides analgesia during induction and maintenance of general anesthesia for major surgery. Epidurally, it is used for labor pain, after cesarean section, and for postoperative analgesia after major abdominal, thoracic, and orthopedic surgery. It is given only by, or under the direct supervision of, an anesthesiologist with immediate access to resuscitation equipment.
Sufentanil, the active ingredient in Sufenta, is one of the most potent opioids in clinical use. It is approximately 5 to 10 times more potent than fentanyl and 500 to 1,000 times more potent than morphine on a weight-for-weight basis. Clinically effective doses are therefore measured in micrograms rather than milligrams. This extreme potency is useful for cardiovascular stability during major surgery but also means that small dosing errors can have large clinical consequences, which is why administration is tightly controlled.
The most important risk is respiratory depression, which can range from mild slowing of breathing to complete apnea. This effect may persist into the recovery period or recur as the drug redistributes from tissue stores. Other serious risks include severe bradycardia, chest wall rigidity that impairs ventilation, hypotension, anaphylaxis, and — very rarely — cardiac arrest. These risks are mitigated by continuous monitoring, immediate availability of naloxone, and the presence of trained personnel throughout drug exposure.
Intravenous Sufenta must not be given during labor or before the umbilical cord is clamped at cesarean section because it crosses the placenta and can depress the newborn's breathing. Epidural Sufenta, however, is widely used for labor analgesia because systemic absorption is low and fetal exposure is minimal. The mother receives effective pain relief while remaining awake and cooperative, and the newborn's respiratory effort is assessed at birth as part of routine care.
Like all opioids, sufentanil has the potential for tolerance, physical dependence, and misuse. The risk of developing opioid use disorder from a single hospital exposure is low, but it is higher in patients with a personal or family history of substance use, untreated mental health conditions, or prolonged opioid therapy. Sufenta is administered only under close medical supervision, with controlled doses and documentation. If you are concerned about your risk, discuss this with your anesthesiologist before surgery so that a tailored post-discharge pain plan can be arranged.
Sufentanil is excreted into breast milk in small amounts. Current expert guidance suggests that breastfeeding can usually be safely resumed approximately 24 hours after the last dose. During this interval you may express and discard milk to maintain supply. If very high doses were used, if you received additional opioids, or if your baby is premature or otherwise vulnerable, the recommended interval may be longer — your medical team will advise.
After a single intravenous bolus, Sufenta has a rapid onset within 1 to 3 minutes and a clinical duration of 20 to 45 minutes depending on dose. With repeated boluses or continuous infusion, peripheral accumulation can prolong the effect significantly. A single epidural bolus typically provides 3 to 6 hours of analgesia, and continuous epidural infusions can provide steady pain relief for days when a catheter is in place.
No. After any anesthetic that includes Sufenta you must not drive, cycle, operate machinery, drink alcohol, or make important legal or financial decisions for at least 24 hours, and longer if you still feel drowsy or mentally slowed. Arrange for a responsible adult to accompany you home and to stay with you overnight after any outpatient procedure.
References and Sources
This article is based on the following peer-reviewed sources, international clinical guidelines, and regulatory documents. Medical claims are aligned with Evidence Level 1A wherever systematic reviews or meta-analyses exist.
- European Medicines Agency (EMA). Sufentanil — Summary of Product Characteristics (SmPC). European Public Assessment Database. Accessed December 2025.
- World Health Organization (WHO). WHO Model List of Essential Medicines — 23rd List, 2023. Geneva: World Health Organization; 2023.
- British National Formulary (BNF). Sufentanil — Drug Monograph. National Institute for Health and Care Excellence (NICE). Updated 2025.
- U.S. Food and Drug Administration (FDA). Sufentanil Citrate Injection — Prescribing Information. FDA Drug Database. Accessed December 2025.
- Scholz J, Steinfath M, Schulz M. “Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil: an update.” Clinical Pharmacokinetics. 1996;31(4):275–292. doi:10.2165/00003088-199631040-00004
- Bailey PL, Streisand JB, East KA, et al. “Differences in magnitude and duration of opioid-induced respiratory depression and analgesia with fentanyl and sufentanil.” Anesthesia & Analgesia. 1990;70(1):8–15.
- Rosow CE. “Sufentanil citrate: a new opioid analgesic for use in anesthesia.” Pharmacotherapy. 1984;4(1):11–19.
- Grass JA. “Sufentanil: clinical use as postoperative analgesic — epidural/intrathecal route.” Journal of Pain and Symptom Management. 1992;7(5):271–286.
- Monk JP, Beresford R, Ward A. “Sufentanil: a review of its pharmacological properties and therapeutic use.” Drugs. 1988;36(3):286–313.
- American Society of Anesthesiologists (ASA). “Practice Guidelines for Perioperative Management of Patients with Opioid Use Disorder.” Anesthesiology. 2023;138(2):218–245.
- European Society of Anaesthesiology and Intensive Care (ESAIC). “Guidelines on perioperative opioid use.” European Journal of Anaesthesiology. 2024.
- Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. “CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022.” MMWR Recomm Rep. 2022;71(3):1–95.
- Cochrane Database of Systematic Reviews. Epidural analgesia for pain after caesarean section. 2020. doi:10.1002/14651858.CD007876.pub3
- Cochrane Database of Systematic Reviews. Epidural versus non-epidural or no analgesia for pain management in labour. 2018. doi:10.1002/14651858.CD000331.pub4
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed physicians with specialist qualifications in anesthesiology, pharmacology, and pain medicine. All content follows the GRADE evidence framework and is reviewed against international medical standards published by the WHO, EMA, FDA, BNF, and major anesthesiology societies.
iMedic Medical Editorial Team — Specialists in Anesthesiology and Clinical Pharmacology, with combined clinical experience across operating rooms, intensive care, and obstetric anesthesia.
iMedic Medical Review Board — Independent expert panel reviewing all content against WHO, EMA, FDA, and BNF guidelines, with documented credentials and no commercial conflicts.
All medical claims are supported by Level 1A evidence where available: systematic reviews and meta-analyses of randomized controlled trials, supplemented by international regulatory documentation.
No pharmaceutical company funding, sponsorship, or advertising. iMedic content is fully independent of manufacturers and is not influenced by commercial interests.